Clinical trials: Ketosis, Diabetic
Type 1 Diabetes
Evaluating the Occurrence of DKA in People With Type I Diabetes
This study will evaluate the occurrences of Diabetes-related Ketoacidosis (DKA) in adult and pediatric individuals living with Type I diabetes while managing diabetes with Abbott's Continuous Monitoring Systems.
- Trial name
- NCT07739342
- Testing
- Abbott Continuous Dual Glucose Ketone Monitoring System
- Where
- 7 sites in New Zealand
- Volunteers
- 1,200 people
- Sponsor
- Abbott Diabetes Care
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2
The BRIGHT Study (Device Name: HALO System)
The purpose of the BRIGHT study is to evaluate safety and performance of the HALO SYSTEM in subjects with diabetes mellitus. The primary objectives of this clinical investigation are 1) the evaluation of sensor's performance by…
- Conditions
- Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Diabetes Mellitus, Ketoacidosis, Diabetic
- Trial name
- NCT07745998
- Testing
- The HALO System
- Volunteers
- 12 people
- Sponsor
- Indigo Diabetes NV
Diabetes Mellitus, Diabetes Mellitus, Type 1
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects
The objectives of SHINE study are to confirm the safety aspects of the SHINE SYSTEM. Moreover, the goal of this clinical investigation is the initial evaluation of sensor's performance by assessing sensor's ability to…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Ketoacidosis, Diabetic
- Trial name
- NCT05597605
- Testing
- The SHINE SYSTEM
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 6 people
- Sponsor
- Indigo Diabetes NV
Healthy Volunteers and Diabetes Participants
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
This is a Phase 1/2 randomized study of oral doses of PAL-119 in healthy volunteers and participants with diabetes.
- Trial name
- NCT07901595
- Testing
- PAL-119
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Paulex Bio Inc.
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Diabetic Ketoacidosis
REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis
A number of scientific papers have been published on the efficacy and safety of adding REAMBERIN® (meglumin sodium succinate), a 1.5% infusion solution, to standard therapy for patients with diabetic ketoacidosis (DKA), which…
- Trial name
- NCT06955416
- Testing
- Reamberin
- Where
- 3 sites in Russia
- Volunteers
- 312 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Diabetes Mellitus, Type 2
Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
The objectives of this study are to assess the risk of ketoacidosis, severe urinary tract infections, volume depletion, and dehydration associated in patients with T2DM initiating Empagliflozin compared to patient initiating a…
- Trial name
- NCT03764631
- Testing
- Empagliflozin, Dipeptidyl-peptidase 4 (DPP-4) inhibitors
- Where
- 21 sites in Saudi Arabia
- Volunteers
- 1,502 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use…
- Trial name
- RECORD-IQ (NCT07211126)
- Testing
- t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)
- Where
- 25 sites in France
- Volunteers
- 350 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Ketosis, Diabetic
StatStrip Glucose/Ketone Meter System Ketone Evaluation
The Nova StatStrip Glucose / Ketone Meter System is a fast, simple, whole blood system that can be used to quantify both glucose and ketones using two distinct test strips.
- Trial name
- NCT05118061
- Testing
- Ketone
- Where
- 3 sites in United States, Germany
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Nova Biomedical
Diabetes Mellitus, Type 2
Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents
The purpose of this study is to compare the incidence of diabetic ketoacidosis (DKA) among participants diagnosed with type 2 diabetes mellitus (T2DM) and pair-matched on exposure propensity scores for new use of any…
- Trial name
- NCT02636192
- Testing
- No Intervention
- Volunteers
- 200,000 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus
EtCO2 for Monitoring and Predicting Severity of DKA in Pediatric Emergency, Doha, Qatar.
Metabolic acidosis is one of the important and life-threatening pathophysiological changes in DKA and its monitoring is essential.
- Trial name
- NCT04121572
- Testing
- Nasal cannula capnography
- Where
- Qatar
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation